KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBITDA Margin (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBITDA Margin data on record, last reported at 21.96% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 811339.0% year-over-year to 21.96%; the TTM value through Dec 2025 reached 32.0%, down 3357.0%, while the annual FY2025 figure was 32.0%, 42.0% up from the prior year.
  • EBITDA Margin reached 21.96% in Q4 2025 per REGN's latest filing, down from 39.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 46488.89% in Q2 2021 and bottomed at 9727.03% in Q2 2024.
  • Average EBITDA Margin over 5 years is 1198.58%, with a median of 29.26% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 4644064bps in 2021, then tumbled -4489209bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 21.74% in 2021, then skyrocketed by 5572bps to 1233.4% in 2022, then crashed by -656bps to 6860.66% in 2023, then fell by -18bps to 8091.43% in 2024, then surged by 100bps to 21.96% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 21.96% in Q4 2025, 39.33% in Q3 2025, and 38.5% in Q2 2025.